Welcome to our dedicated page for CUR news (Ticker: CUR), a resource for investors and traders seeking the latest updates and insights on CUR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CUR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CUR's position in the market.
NeuroRx announced the dosing of the first patient in its P2/3 clinical trial of inhaled ZYESAMI™ for moderate to severe COVID-19 at the University of California Irvine. The AVICOVID-2 trial will span 10-15 US clinical sites, with three sites already initiated. CEO Jonathan C. Javitt emphasized the study aims to prevent respiratory failure in COVID-19 patients, highlighting the company's commitment despite challenges. ZYESAMI™ targets alveolar type II cells and aims to block SARS-CoV-2 replication, potentially offering a novel treatment approach.
